EUVIMEDEUVIMED entdecken
Crossref

Real‐World Experience of 3‐Year Treatment With Dupilumab: Significant Decrease in Circulating Neutrophils and Eosinophils in Japanese Patients With Atopic Dermatitis

Hideyuki Nakajima, Masahiro Kamata iD, Yoshiki Okada, Shoya Suzuki, Makoto Ito, Ayu Watanabe, Shota Egawa, Chika Chijiwa, Azusa Hiura, Yayoi Tomura, Saki Fukaya, Kotaro Hayashi und 4 weitere

Experimental Dermatology · 2024

DOI: 10.1111/exd.70010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Experimental Dermatology, 2024. Verfasst von Hideyuki Nakajima und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Teikyo University School of Medicine, Itabashi-ku, Tokyo, Japan. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Humanized, Eosinophils, Neutrophils. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dupilumab, an anti‐interleukin (IL)‐4 receptor α‐antibody, was approved in 2018 for the treatment of moderate‐to‐severe atopic dermatitis (AD) in Japan. Although real‐world data have accumulated on the effectiveness and safety of dupilumab in patients with AD in the short term, real‐world data on its long‐term use are limited. In this study, we retrospectively investigated its effectiveness, safety and laboratory data in patients with AD who received dupilumab for 3 years. All adult patients with moderate‐to‐severe AD who were administered dupilumab between June 2018 and December 2020 and were treated with dupilumab for more than 3 years were included in this study. Sixty Japanese patients with AD (male, 48; female, 12) were included in this study. Their mean age was 36.6 ± 11.0 (standard deviation) years. The mean Eczema Area and Severity Index (EASI) was 29.9 ± 9.2. The clinical severity scales, including Investigator's Global Assessment (IGA), EASI and affected body surface area (BSA), and patient‐reported outcomes, such as Dermatology Quality Life Index (DLQI), Patient‐Oriented Eczema Measure (POEM) and visual analogue scale (VAS) of pruritus, significantly improved at 3 months, and at 1, 2 and 3 years after initiating dupilumab. The total EASI score significantly decreased by a mean of 66.8% at 3 months, 81.0% at 1 year, 85.3% at 2 years and 90.0% at 3 years after initiating dupilumab. The serum levels of thymus and activation‐regulated chemokine (TARC), immunoglobulin E (IgE) and lactate dehydrogenase (LDH) significantly decreased at 1, 2 and 3 years. A slight decrease in circulating neutrophils was observed in patients with AD treated with dupilumab over periods from 3 months to 3 years. The number of circulating eosinophils significantly decreased at 2 and 3 years after initiating dupilumab. The most common adverse event was ocular disorders observed in 23 patients (38.3%). Our study shows the sustained effectiveness and tolerable safety of 3‐year usage of dupilumab in Japanese patients with atopic dermatitis. Furthermore, dupilumab decreased neutrophil values at 3 months and later, and reduced the number of circulating eosinophils after long‐term use (≧ 2 years).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicAntibodies, Monoclonal, HumanizedEosinophilsNeutrophilsHumansFemaleMaleAdultMiddle AgedRetrospective StudiesJapanSeverity of Illness IndexYoung AdultTreatment OutcomeQuality of LifeEast Asian People

Stichwörter der Autor:innen

atopic dermatitisdupilumabinterleukin‐4long‐termreal‐world

Substanzen

dupilumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Dermatology, Teikyo University School of Medicine, Itabashi-ku, Tokyo, Japan.

ORCID-Profile: Masahiro Kamata

Zitieren

APA

Nakajima, H., Kamata, M., Okada, Y., Suzuki, S., Ito, M., Watanabe, A., Egawa, S., Chijiwa, C., Hiura, A., Tomura, Y., Fukaya, S., Hayashi, K., Fukuyasu, A., Tanaka, T., Ishikawa, T., & Tada, Y. (2024). Real‐World Experience of 3‐Year Treatment With Dupilumab: Significant Decrease in Circulating Neutrophils and Eosinophils in Japanese Patients With Atopic Dermatitis. Experimental Dermatology. https://doi.org/10.1111/exd.70010

Vancouver

Nakajima H, Kamata M, Okada Y, Suzuki S, Ito M, Watanabe A, et al. Real‐World Experience of 3‐Year Treatment With Dupilumab: Significant Decrease in Circulating Neutrophils and Eosinophils in Japanese Patients With Atopic Dermatitis. Experimental Dermatology. 2024. doi:10.1111/exd.70010

BibTeX
@article{Nakajima2024,
  author = {Nakajima, Hideyuki and Kamata, Masahiro and Okada, Yoshiki and Suzuki, Shoya and Ito, Makoto and Watanabe, Ayu and Egawa, Shota and Chijiwa, Chika and Hiura, Azusa and Tomura, Yayoi and Fukaya, Saki and Hayashi, Kotaro and Fukuyasu, Atsuko and Tanaka, Takamitsu and Ishikawa, Takeko and Tada, Yayoi},
  title = {Real‐World Experience of 3‐Year Treatment With Dupilumab: Significant Decrease in Circulating Neutrophils and Eosinophils in Japanese Patients With Atopic Dermatitis},
  journal = {Experimental Dermatology},
  year = {2024},
  doi = {10.1111/exd.70010}
}
Kostenlos starten →